Payment overview · 2025
General Payments
$14,473.40
201 reported records · 38 companies
Healthcare provider profile · identity verified
Mark Alan Scheperle, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1265417034
Verified facts
What the public records show
CMS Open Payments records show Mark Alan Scheperle, M.D. received $14,473.40 in general payments during 2025 across 201 reported records.
Gilead Sciences, Inc. accounted for 76.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 61 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato, Eliquis, Farxiga, Mounjaro, Mytesi, Ozempic, Paxlovid, Pifeltro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Pifeltro by this doctor in 2024.
Napo Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mytesi as an associated drug or biological on 1178 records involving 562 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mytesi by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $11,007.92 | 76.1% | 33 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $767.38 | 5.3% | 33 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $334.49 | 2.3% | 21 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $279.63 | 1.9% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $278.31 | 1.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $201.12 | 1.4% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $170.93 | 1.2% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $165.30 | 1.1% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $160.51 | 1.1% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $97.77 | 0.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $85.99 | 0.6% | 4 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $82.33 | 0.6% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $80.51 | 0.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.20 | 0.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.85 | 0.3% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.00 | 0.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.13 | 0.3% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $40.83 | 0.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.01 | 0.3% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $36.50 | 0.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $35.38 | 0.2% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.23 | 0.2% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $34.21 | 0.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.91 | 0.2% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $30.93 | 0.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.78 | 0.2% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.02 | 0.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25.51 | 0.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.81 | 0.2% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.50 | 0.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.55 | 0.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.69 | 0.2% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $21.19 | 0.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.56 | 0.1% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $19.61 | 0.1% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.60 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.49 | 0.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.72 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,570.00 | 4 |
| Food and Beverage | $4,286.00 | 194 |
| Travel and Lodging | $1,617.40 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $8,482.50 | 12 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $279.63 | 8 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $250.73 | 11 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $198.04 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $173.74 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $165.30 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $163.40 | 6 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $161.18 | 5 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $157.43 | 8 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $134.57 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $129.09 | 14 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.24 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $90.66 | 12 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $85.99 | 4 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $82.33 | 4 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $82.33 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $80.51 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $77.30 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $75.07 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.20 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $64.09 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $61.12 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.09 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.20 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.85 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.85 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $34.21 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $34.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $33.68 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $30.93 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| THIRD WAVE Normalized: third wave |
Device | Hologic Sales and Service, LLC | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 217 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Mytesi mytesi |
2025 | Mytesi | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
217 | 33 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Napo Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Mytesi open payments reported associated product |
CMS Open Payments — General Payments 1178 supporting records · 562 recipient NPIs · example record 1223618503 |
Mytesi · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 406 | 71 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 342 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 78 |
| Oxycodone Hcl | Oxycodone Hcl | 246 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 227 | 69 |
| Lisinopril | Lisinopril | 224 | 65 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 217 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 57 |
| Alprazolam | Alprazolam | 209 | 50 |
| Losartan Potassium | Losartan Potassium | 173 | 50 |
| Omeprazole | Omeprazole | 172 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 36 |
| Gabapentin | Gabapentin | 142 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 39 |
| Morphine Sulfate Er | Morphine Sulfate | 128 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 36 |
| Meloxicam | Meloxicam | 98 | 30 |
| Montelukast Sodium | Montelukast Sodium | 95 | 24 |
| Trazodone Hcl | Trazodone Hcl | 91 | 37 |
| Metformin Hcl | Metformin Hcl | 90 | 34 |
| Bupropion Xl | Bupropion Hcl | 88 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 23 |
| Allopurinol | Allopurinol | 81 | 21 |
| Lorazepam | Lorazepam | 77 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 20 |
| Dovato | Dolutegravir Sodium/Lamivudine | 74 | suppressed |
| Ozempic | Semaglutide | 74 | 16 |
| Simvastatin | Simvastatin | 72 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 21 |
| Pifeltro | Doravirine | 70 | suppressed |
| Celecoxib | Celecoxib | 69 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 68 | 18 |
| Tivicay | Dolutegravir Sodium | 68 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 68 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 19 |
| Fentanyl | Fentanyl | 64 | suppressed |
| Prednisone | Prednisone | 62 | 18 |
| Tramadol Hcl | Tramadol Hcl | 62 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 12 |
| Descovy | Emtricitabine/Tenofov Alafenam | 55 | suppressed |
| Carvedilol | Carvedilol | 53 | 13 |
| Oxycontin | Oxycodone Hcl | 53 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 18 |
| Finasteride | Finasteride | 51 | 16 |
| Famotidine | Famotidine | 50 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 13 |
| Furosemide | Furosemide | 48 | 14 |
| Eliquis | Apixaban | 46 | 11 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 30 |
| Baclofen | Baclofen | 43 | suppressed |
| Fenofibrate | Fenofibrate | 43 | 13 |
| Azithromycin | Azithromycin | 41 | 30 |
| Minoxidil | Minoxidil | 41 | 11 |
| Prezcobix | Darunavir/Cobicistat | 41 | suppressed |
| Serostim | Somatropin | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 21 |
| Testosterone | Testosterone | 41 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Diazepam | Diazepam | 39 | 12 |
| Potassium Chloride | Potassium Chloride | 38 | 14 |
| Sertraline Hcl | Sertraline Hcl | 37 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Buspirone Hcl | Buspirone Hcl | 34 | 11 |
| Ibuprofen | Ibuprofen | 34 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 33 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Temazepam | Temazepam | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 15 |
| Mytesi | Crofelemer | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ritonavir | Ritonavir | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 16 | suppressed |
| Ivermectin | Ivermectin | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Darunavir | Darunavir | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Maraviroc | Maraviroc | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Alprazolam Er | Alprazolam | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Etravirine | Etravirine | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Efavirenz | Efavirenz | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Fosamprenavir Calcium | Fosamprenavir Calcium | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,473.40 · 201 records | Gilead Sciences, Inc. | ABRYSVO, AIRSUPRA, APRETUDE, APTIMA, AUSTEDO XR, AZMIRO, Auvelity, BREZTRI, Belbuca, Biktarvy, CABENUVA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, DOVATO, Dyanavel XR, EGRIFTA, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, HORIZANT, INCEPTIV, KEVEYIS, Kerendia, LEQVIO, LINZESS, MAVYRET, MOUNJARO, Mytesi, NP Thyroid 60, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, PIFELTRO, PREVNAR 20, QULIPTA, REPATHA, RUKOBIA, Senza, Symbravo, THINPREP 2000 PROCESSOR, THIRD WAVE, TRELEGY ELLIPTA, TRINTELLIX, TROGARZO, Tlando, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error